MUC1 and non-small cell lung carcinoma: The First People’s Hospital of Hefei, China, is about to complete a phase I/II study of MUC1-CAR T cells in patients with MUC1+ advanced refractory NSCLC (NCT02587689), and is close to completing a similar ongoing study in which MUC1-CAR-pNK cells (with CAR structures implanted into placenta-derived NK cells) are applied in patients with advanced refractory NSCLC (NCT02839954).